AMAG Pharmaceuticals, Inc. to Host Conference Call on April 25, 2008 to Discuss Financial Results for the Quarter Ended March 31, 2008.CAMBRIDGE, Mass. -- AMAG AMAG African Microbicides Advocacy Group AMAG Agricultural Machinery Advisory Group Pharmaceuticals, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : AMAG) today announced it will report unaudited consolidated financial results for the quarter ended March 31, 2008 before the U.S. financial markets open on Friday, April 25, 2008. The announcement will be followed by a conference call at 8:00 a.m. ET during which management will discuss the Company's financial results, business highlights and its development programs. To access the conference call via telephone, please dial (877) 412-6083 from the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. or (706) 902-1303 for international access. A telephone replay will be available from approximately 11:00 a.m. ET on April 25, 2008 through midnight April 29, 2008. To access a replay of the conference call, dial (800) 642-1687 from the United States or (706) 645-9291 for international access. The passcode for the live call and replay is 43018810. An audio webcast of the call will be available through the Investors section of the Company's website at www.amagpharma.com. The webcast replay will be available from approximately 11:00 a.m. ET on April 25, 2008 through midnight May 25, 2008. About AMAG Pharmaceuticals, Inc. AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease Cardiovascular disease Disease that affects the heart and blood vessels. Mentioned in: Lipoproteins Test cardiovascular disease . Ferumoxytol, the Company's key product candidate, is being developed for use as an intravenous iron replacement therapeutic for the treatment of iron deficiency anemia Iron Deficiency Anemia Definition Anemia can be caused by iron deficiency, folate deficiency, vitamin B12 deficiency, and other causes. The term iron deficiency anemia means anemia that is due to iron deficiency. in chronic kidney disease Chronic kidney disease (CKD), also know as chronic renal disease, is a progressive loss of renal function over a period of months or years through five stages. Each stage is a progression through an abnormally low and progressively worse glomerular filtration rate, which is patients. The Company has released data on all four planned Phase III clinical trials of ferumoxytol as an intravenous iron replacement therapeutic in chronic kidney disease patients. The Company submitted a New Drug Application for marketing approval of ferumoxytol with the U.S. Food and Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) in December 2007, which was accepted for filing by the FDA in February 2008. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion